The Cigna Group (NYSE:CI) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its position in The Cigna Group (NYSE:CI - Free Report) by 2.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 110,114 shares of the health services provider's stock after selling 3,132 shares during the period. Nisa Investment Advisors LLC's holdings in The Cigna Group were worth $32,974,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Bogart Wealth LLC boosted its position in shares of The Cigna Group by 104.5% during the third quarter. Bogart Wealth LLC now owns 90 shares of the health services provider's stock valued at $26,000 after buying an additional 46 shares during the last quarter. OFI Invest Asset Management purchased a new position in The Cigna Group in the third quarter worth $26,000. Fortitude Family Office LLC purchased a new position in The Cigna Group in the fourth quarter worth $29,000. Fairfield Bush & CO. purchased a new position in The Cigna Group in the second quarter worth $28,000. Finally, VisionPoint Advisory Group LLC boosted its position in The Cigna Group by 112.2% in the third quarter. VisionPoint Advisory Group LLC now owns 104 shares of the health services provider's stock worth $30,000 after purchasing an additional 55 shares during the last quarter. Institutional investors and hedge funds own 86.99% of the company's stock.

The Cigna Group Stock Up 0.6 %

Shares of NYSE:CI traded up $2.08 during trading on Friday, hitting $362.45. The stock had a trading volume of 991,825 shares, compared to its average volume of 1,390,451. The Cigna Group has a 12 month low of $240.50 and a 12 month high of $365.71. The company has a market capitalization of $105.97 billion, a PE ratio of 20.84, a PEG ratio of 1.11 and a beta of 0.56. The firm's fifty day moving average is $341.57 and its 200 day moving average is $311.45. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 0.61.

The Cigna Group (NYSE:CI - Get Free Report) last posted its quarterly earnings data on Friday, February 2nd. The health services provider reported $6.79 earnings per share for the quarter, beating analysts' consensus estimates of $6.54 by $0.25. The Cigna Group had a return on equity of 13.59% and a net margin of 2.64%. The company had revenue of $51.15 billion during the quarter, compared to analyst estimates of $48.91 billion. During the same quarter last year, the company earned $4.96 EPS. The firm's revenue for the quarter was up 11.8% on a year-over-year basis. Analysts anticipate that The Cigna Group will post 28.36 EPS for the current fiscal year.

The Cigna Group Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 21st. Stockholders of record on Wednesday, March 6th were paid a $1.40 dividend. This is an increase from The Cigna Group's previous quarterly dividend of $1.23. This represents a $5.60 dividend on an annualized basis and a dividend yield of 1.55%. The ex-dividend date of this dividend was Tuesday, March 5th. The Cigna Group's dividend payout ratio (DPR) is 32.20%.

Wall Street Analyst Weigh In

Several research firms have weighed in on CI. Deutsche Bank Aktiengesellschaft raised The Cigna Group from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $355.00 to $370.00 in a research report on Thursday, February 1st. Barclays began coverage on The Cigna Group in a research note on Wednesday, March 6th. They issued an "overweight" rating and a $393.00 target price on the stock. Royal Bank of Canada upgraded The Cigna Group from a "sector perform" rating to an "outperform" rating and boosted their target price for the company from $327.00 to $354.00 in a research note on Monday, February 5th. Oppenheimer restated an "outperform" rating and issued a $360.00 target price on shares of The Cigna Group in a research note on Wednesday, January 17th. Finally, StockNews.com upgraded The Cigna Group from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 14th. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, The Cigna Group currently has a consensus rating of "Buy" and an average target price of $361.29.

Insider Transactions at The Cigna Group

In other news, CEO David Cordani sold 31,209 shares of the firm's stock in a transaction on Monday, March 25th. The stock was sold at an average price of $355.17, for a total value of $11,084,500.53. Following the transaction, the chief executive officer now directly owns 348,054 shares in the company, valued at approximately $123,618,339.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, SVP Hoeltzel Mary T. Agoglia sold 4,867 shares of The Cigna Group stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $330.48, for a total transaction of $1,608,446.16. Following the transaction, the senior vice president now directly owns 2,102 shares in the company, valued at $694,668.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David Cordani sold 31,209 shares of The Cigna Group stock in a transaction on Monday, March 25th. The shares were sold at an average price of $355.17, for a total value of $11,084,500.53. Following the transaction, the chief executive officer now owns 348,054 shares in the company, valued at $123,618,339.18. The disclosure for this sale can be found here. Insiders have sold a total of 114,144 shares of company stock worth $39,296,330 in the last ninety days. Insiders own 0.60% of the company's stock.

About The Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.